Fundz

Surge Therapeutics reported raising $32 Million in an initial SEC Form D filing, from an offering of $50 Million

PRIVATEJun 02, 2023$32M of $50M raised

Amount Raised

$32 Million

$32 Million sold, per SEC Form D (first sale May 19, 2023)

Round Type

Venture

CambridgeBiotechnologyHealth CareTherapeutics

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as SURGE Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Actym Therapeutics raised $11M on June 28, 2023.
  • Foresee Pharmaceuticals raised $42M (Funding Round) on June 27, 2023.
  • Actimed Therapeutics raised an undisclosed amount (Series A) on June 26, 2023.
  • DiaMedica Therapeutics raised $38M on June 23, 2023.
  • Calidi Biotherapeutics raised an undisclosed amount (Series B) on June 23, 2023.
  • Pharvaris raised $70M (Post-IPO Equity) on June 20, 2023.

Who to call at SURGE Therapeutics, and when

A new round usually means SURGE Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day SURGE Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at SURGE Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at SURGE Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

SURGE Therapeutics

Location

Cambridge, Maryland, United States

About

SURGE seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed -- focusing 100% of the effective dose at the right place and at the right time. Surgery is the standard of care for most patients with solid tumors, and we are working tirelessly to ensure that nobody grieves the loss of a loved one to preventable post-surgical cancer recurrence.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment SURGE Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsMICHAEL G., CEO hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for SURGE Therapeutics's next move

See what Strategic adds

SURGE Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.